Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Geron is a biopharmaceutical company developing first-in-class therapies for cancer and chronic degenerative diseases. Key programs include imetelstat (telomerase inhibitor), GRNVAC1 (cancer vaccine), and human embryonic stem cell (hESC) therapies such as GRNOPC1 for spinal cord injury. The company operates as a single segment focused on discovery and development.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Balance Sheet (Sep 30, 2009) |
|---|---|---|---|
| Total Revenues | $494 | $1,121 | N/A |
| Net Loss | $(15,224) | $(51,793) | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.17) | $(0.59) | N/A |
| Research & Development Expenses | $13,395 | $42,278 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $97,869 |
| Marketable Securities | N/A | N/A | $80,748 |
| Total Current Assets | N/A | N/A | $184,683 |
| Total Current Liabilities | N/A | N/A | $9,359 |
| Accumulated Deficit | N/A | N/A | $(558,876) |
Liquidity: As of September 30, 2009, the company held approximately $179.4 million in cash, restricted cash, cash equivalents, and marketable securities. Management estimates these resources are sufficient to fund operations through at least December 2010.
Material Changes vs. Prior Period
- Revenues: Total revenues for the nine months ended September 30, 2009, decreased to $1.12 million from $2.26 million in the prior year period. This decline was primarily due to the absence of a $1.5 million milestone payment recognized in 2008 related to the FDA's risk assessment on cloned animals. 2009 revenues were driven by the new collaboration with GE Healthcare.
- Net Loss: The net loss for the nine months increased to $51.8 million from $44.4 million in the prior year. This increase was driven by higher research and development expenses ($42.3 million vs. $39.4 million), decreased interest income due to lower rates, and reduced milestone revenues.
- Operating Expenses: Research and development expenses increased by approximately $2.8 million year-over-year for the nine-month period, attributed to increased clinical trial costs for imetelstat and GRNVAC1 and higher personnel costs. General and administrative expenses decreased by $1.5 million due to reduced legal and consulting costs.
- Cash Flow: Net cash used in operating activities increased slightly to $31.8 million from $30.6 million. Net cash provided by financing activities was $51.5 million, primarily due to a public offering in February 2009 yielding $45.9 million in net proceeds and a September 2009 private placement yielding $3.6 million.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Management expects to recognize approximately $175,000 in revenue for the remainder of 2009, $700,000 in 2010, and $350,000 in 2011 from existing deferred revenue.
- Research and development expenses are expected to increase as clinical trials for imetelstat and GRNVAC1 progress and hESC programs continue.
- The company anticipates needing substantial additional capital in the future to fund operations and may seek funding through strategic collaborations or equity financings.
- Imetelstat: Preliminary data from clinical trials showed safety and tolerability. Interim data in multiple myeloma patients showed the first evidence in humans of telomerase inhibition.
- GRNOPC1 (Spinal Cord Injury): The human clinical trial has been placed on clinical hold by the FDA. The company is in discussions with the agency to resolve questions and proceed.
- GE Healthcare Collaboration: A new exclusive license and alliance agreement was entered into in June 2009 to develop cellular assay products derived from hESCs.
- Regulatory Risk: The clinical hold on GRNOPC1 and the uncertainty of FDA approvals for all product candidates pose significant risks.
- Financial Risk: The company has a history of losses with an accumulated deficit of $559 million. Continued losses could impair the ability to sustain operations without additional financing.
- Intellectual Property: Ongoing patent oppositions in Europe (e.g., against Pharmexa) and reexaminations in the U.S. (e.g., WARF patents) create uncertainty regarding proprietary rights.
- Market Risk: The company is exposed to interest rate risk and foreign currency exchange risk, though management deems the exposure immaterial.
Key Facts for Investor Verification
- Cash Runway: Verify if the $179.4 million in liquid assets is sufficient to fund the accelerated clinical trial costs for imetelstat and GRNVAC1 through the projected December 2010 date.
- GRNOPC1 Status: Monitor the resolution of the FDA clinical hold on the spinal cord injury therapy, as this is a critical milestone for the hESC platform.
- Revenue Sustainability: Assess the reliance on collaboration revenues (GE Healthcare) versus the lack of product sales, noting the significant drop in milestone revenue compared to 2008.
- Patent Litigation: Track the outcome of the European patent opposition regarding telomerase vaccines and the U.S. reexamination of WARF hESC patents, as these are critical to the company's IP portfolio.
- Derivative Liabilities: Note the $1.34 million liability for derivatives (warrants/options) which fluctuates with stock price and impacts net loss calculations.